Beese Fulmer Investment Management Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 93,723 shares of the company’s stock after selling 796 shares during the period. Johnson & Johnson comprises 3.2% of Beese Fulmer Investment Management Inc.’s holdings, making the stock its largest position. Beese Fulmer Investment Management Inc.’s holdings in Johnson & Johnson were worth $11,369,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Americafirst Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. INR Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $150,000. Capital Asset Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $202,000. NewSquare Capital LLC boosted its stake in shares of Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares during the last quarter. Finally, Shayne & CO. LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $219,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.59% on Friday, reaching $117.56. 5,640,519 shares of the company traded hands. The firm’s 50 day moving average is $118.72 and its 200 day moving average is $117.37. The company has a market capitalization of $321.63 billion, a P/E ratio of 21.91 and a beta of 0.62. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

A number of brokerages have recently weighed in on JNJ. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. BMO Capital Markets restated an “outperform” rating and issued a $132.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Wells Fargo & Co. restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. Jefferies Group boosted their price objective on shares of Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a research note on Thursday, August 4th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $142.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $120.19.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.